How do you approach treatment of patients with metastatic HR+ breast cancer with detection of ESR1 mutation after initiation of an AI and CDK4/6 Inhibitor?
How does data from PADA1 and EMERALD trials presented at SABCS 2021 impact your decision making?
Answer from: Medical Oncologist at Academic Institution
In PADA-1 (SABCS 2021), the development of an ESR1 mutation, regardless of progression on scans, followed by the continuation of palbociclib but changing to fulvestrant, was associated with a PFS of 11.9 m. If one waited until clinical progression, then treated with fulvestrant and palbociclib, the ...
Sign in or Register to read more